68Ga-FAPI仅摄取:罕见转移性高分化1级胰腺神经内分泌肿瘤
一例36岁女性高分化1级胰腺神经内分泌肿瘤患者,以严重右上腹疼痛和呕吐起病,68Ga-DOTANOC及18F-FDG PET/CT均为阴性,而68Ga-FAPI-04 PET/CT显示胰腺原发灶及肝转移灶呈强烈摄取。提示在SSTR及FDG双阴性NET中,FAPI显像可能补充检出病灶。
要点
- SSTR显像是高分化NET分期及寻找原发灶的首选模态。
- SSTR阴性时可考虑18F-FDG PET/CT以排除肿瘤异质性。
- 本例68Ga-DOTANOC与18F-FDG均阴性,68Ga-FAPI-04检出原发灶及肝转移。
核心结论
- 在高分化1级胰腺NET中,68Ga-DOTANOC与18F-FDG PET/CT可均为阴性,而68Ga-FAPI-04 PET/CT显示胰腺原发灶及肝转移灶强烈摄取。
研究设计与样本
- 本文为个案报道,对象为一名36岁女性高分化1级NET患者,初诊表现为严重右上腹疼痛和呕吐。
主要发现
- 68Ga-DOTANOC PET/CT阴性,随后18F-FDG PET/CT亦阴性。
- 68Ga-FAPI-04 PET/CT显示胰腺原发灶和肝转移灶呈强烈示踪剂摄取。
临床怎么用
- 对SSTR显像阴性的高分化NET,可按原文思路行18F-FDG PET/CT排除肿瘤异质性。
- 当SSTR与FDG PET/CT均阴性而临床仍怀疑NET时,68Ga-FAPI-04 PET/CT可能有助于定位原发灶及转移灶。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Somatostatin receptor (SSTR) imaging is the preferred modality for staging well-differentiated neuroendocrine tumors (NETs) and detecting unknown primary NETs. If SSTR imaging is negative, 18F-FDG PET/CT may be done to rule out tumor heterogeneity. We report a case of a 36-year-old woman with a well-differentiated grade I NET, who initially presented with severe right hypochondriac pain and vomiting. Standard diagnostic workup with 68Ga-DOTANOC followed by 18F-FDG PET/CT was negative; however, 68Ga-FAPI-04 PET/CT demonstrated intense tracer-avid lesions in pancreatic primary and liver metastases.
引用
- Singareddy CTR, Baa AK, Kankara SR, et al. Seeing Beyond 68GA-DOTANOC and 18F-FDG PET/CT: 68GA-FAPI Only Uptake in a Rare Metastatic Well-differentiated Grade I Pancreatic Neuroendocrine Tumor. Clin Nucl Med. 2026. PMID: 42410759. doi:10.1097/RLU.0000000000006389
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。